A Bayesian adaptive randomized phase II multicenter trial of bevacizumab with or without vorinostat in adults with recurrent glioblastoma

BACKGROUND: Bevacizumab has promising activity against recurrent glioblastoma (GBM). However, acquired resistance to this agent results in tumor recurrence. We hypothesized that vorinostat, a histone deacetylase (HDAC) inhibitor with anti-angiogenic effects, would prevent acquired resistance to beva...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Neuro Oncol
Päätekijät: Puduvalli, Vinay K, Wu, Jing, Yuan, Ying, Armstrong, Terri S, Vera, Elizabeth, Wu, Jimin, Xu, Jihong, Giglio, Pierre, Colman, Howard, Walbert, Tobias, Raizer, Jeffrey, Groves, Morris D, Tran, David, Iwamoto, Fabio, Avgeropoulos, Nicholas, Paleologos, Nina, Fink, Karen, Peereboom, David, Chamberlain, Marc, Merrell, Ryan, Penas Prado, Marta, Yung, W K Alfred, Gilbert, Mark R
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Oxford University Press 2020
Aiheet:
Clinical Investigations
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7686463/
https://ncbi.nlm.nih.gov/pubmed/32166308
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa062
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia